J. P. Stein, G. Lieskovsky, and R. Cote, Radical cystectomy in the treatment of invasive bladder cancer. Long-term results in 1054 patients, J. Clin. Oncol, vol.19, pp.666-675, 2001.

S. F. Shariat, P. I. Karakiewicz, and G. S. Palapattu, Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder cancer Research Consortium, J. Urol, vol.176, pp.2414-2422, 2006.

M. I. Milowsky, R. B. Rumble, and C. M. Booth, American society of clinical oncology clinical practice guideline endorsement, J. Clin. Oncol, vol.34, pp.1945-1952, 2016.

A. Witjes, T. Lebret, and E. M. Comperat, Updated 2016 EAU Guidelines on muscle invasive and metastatic bladder cancer, Eur. Urol, vol.71, pp.462-475, 2017.

C. N. Sternberg, P. De-mudler, and J. H. Schornagel, Seven year update of an EORTC phase III trial of high dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumors, Eur. J. Canc, vol.42, pp.50-54, 2006.

T. K. Choueiri, S. Jacobus, and J. Bellemut, Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin and cisplatin with pegfilgrastim support in muscle invasive urothelial cancer : pathologic, radiologic and biomarker correlates, J. Clin. Oncol, vol.32, pp.1882-1894, 2014.

E. R. Plimack, J. H. Hoffman-censits, and R. Viterbo, Accelerated methotrexate, vinblastine, doxorubicin and cisplatin is safe, effective and efficient neoadjuvant treatment for muscle invasive bladder cancer. Results of a multicenter phase II study with molecular correlates of response and toxicity, J. Clin. Oncol, vol.32, pp.1895-1901, 2014.

A. Front, M. Taron, and J. L. Gago, BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer, Ann. Oncol, vol.22, pp.139-144, 2011.

W. Choi, S. Porten, and . Kim, Identification of distinct basal and luminal subtypes of muscle invasive bladder cancer with different sensitivities to front-line chemotherapy, Canc. Cell, vol.25, pp.152-165, 2014.

E. R. Plimack, R. L. Dunbrack, and T. A. Brennan, Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer, Eur. Urol, vol.68, pp.959-967, 2015.

R. Seiler, H. A. Ashab, and N. Erho, Impact of molecular subtypes in muscleinvasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy, Eur. Urol, vol.72, pp.544-554, 2017.

, International Collaboration of Trialists, Neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy for muscle invasive bladder cancer. A randomised controlled trial, Lancet, vol.354, pp.533-540, 1999.

H. B. Grossman, R. B. Natale, and C. M. Tangen, Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advancer bladder cancer, N. Engl. J. Med, vol.349, pp.859-866, 2003.

Z. D. Reardon, S. G. Patel, and . Zaid, Trends in use of perioperative chemotherapy for localized and locally advanced muscle invasive bladder cancer : a sign of changing tides, Eur. Urol, vol.67, pp.165-170, 2015.

C. M. Booth, S. Karim, and K. Brennan, Perioperative chemotherapy for bladder cancer in the general population : are practice patterns finally changing ?, Urol. Oncol, vol.36, 2018.

S. Culine, Y. Allory, and C. Pfister, Refining the use of neoadjuvant chemotherapy in locally advanced bladder cancer : from conviction to optimization, Transl. Androl. Urol, vol.7, pp.757-759, 2018.

H. Zargar, J. B. Shah, and B. W. Van-rhijn, Neoadjuvant dose dense MVAC versus gemcitabine and cisplatin in patients with cT3-4a N0M0 bladder cancer treated with radical cystectomy, J. Urol, vol.199, pp.1452-1458, 2018.

F. Petrelli, A. Coinu, and M. Cabiddu, Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy : a meta-analysis, Eur. Urol, vol.65, pp.350-357, 2014.

D. Robins, J. Matulay, and M. Lipsky, Outcomes following complete response to neo-adjuvant chemotherapy for muscle invasive urothelial carcinoma of the bladder in patients refusing radical cystectomy, Oncology, vol.11, pp.116-121, 2018.

J. E. Rosenberg, J. Hoffman-censits, and T. Powles, Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase II trial, Lancet, vol.387, pp.1909-1920, 2016.

J. Bellmunt, R. Wit, and D. J. Vaughn, Pembrolizumab as second-line therapy for advanced urothelial carcinoma, N. Engl. J. Med, vol.376, pp.1015-1026, 2017.

T. Powles, J. P. Eder, and G. D. Fine, MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer, Nature, vol.515, pp.558-562, 2014.